Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$1.81
−$0.12 · -6.22%
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Previous close
$1.81
−$0.12 · -6.22%
After-hours
$1.81
$0.00 · 0.00%
Oct 12, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Day range
Current $1.81
52-week range
Current $1.81
Regular session · ET · Market data may be delayed.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Day range
Current $1.81
52-week range
Current $1.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.21M USD | 5.82M USD | 4.91M USD | 224K USD | — |
| Cost of goods sold | 445K USD | 852K USD | 9.69M USD | 712K USD | 66K USD |
| Gross profit | 4.77M USD | 4.97M USD | −4.78M USD | −488K USD | −66K USD |
| Research and development | 8.38M USD | 10.58M USD | 9.69M USD | 9.7M USD | 5.32M USD |
| Selling, general, and administrative | 12.13M USD | 9.94M USD | 8.54M USD | 9.53M USD | 6.85M USD |
| Operating expenses | 20.07M USD | 19.67M USD | 8.54M USD | 19.22M USD | 12.43M USD |
| Interest income | 116K USD | 273K USD | 400K USD | 147K USD | 19K USD |
| Interest expense | 3.61M USD | 3.72M USD | 395K USD | 711K USD | 932K USD |
| Depreciation and amortization | 445K USD | 872K USD | 628K USD | 619K USD | 395K USD |
| Operating income | −15.3M USD | −14.7M USD | −13.32M USD | −19.71M USD | −12.49M USD |
| Net income | −22.39M USD | −12.98M USD | −13.32M USD | −20.28M USD | −13.4M USD |
Company facts updated Oct 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 2, 2026 | 1:25 | — | — |
Stock split | May 1, 2023 | 1:15 | — | — |
Stock split | Aug 6, 2019 | 1:50 | — | — |
Stock split | May 24, 2018 | 1:10 | — | — |
Stock split | May 12, 2016 | 1:15 | — | — |
Effective Apr 2, 2026
1:25
Effective May 1, 2023
1:15
Effective Aug 6, 2019
1:50
Effective May 24, 2018
1:10
Effective May 12, 2016
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
